Short Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Decreases By 6.8%

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 11,600,000 shares, a decline of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily volume of 628,500 shares, the days-to-cover ratio is presently 18.5 days.

Atossa Therapeutics Price Performance

Shares of NASDAQ:ATOS opened at $1.04 on Wednesday. The stock has a market capitalization of $130.83 million, a P/E ratio of -4.73 and a beta of 1.21. The business has a 50-day moving average of $1.34 and a two-hundred day moving average of $1.32. Atossa Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $2.31.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ATOS. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Thursday, December 12th. StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Finally, Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in Atossa Therapeutics during the second quarter valued at approximately $29,000. Intech Investment Management LLC bought a new stake in shares of Atossa Therapeutics during the 3rd quarter worth $29,000. SG Americas Securities LLC grew its stake in Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after buying an additional 30,037 shares during the last quarter. Cetera Advisors LLC bought a new position in Atossa Therapeutics in the 1st quarter worth $72,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Atossa Therapeutics during the 3rd quarter worth $75,000. 12.74% of the stock is owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.